Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93–94

HOS-110701 · Präparat HOS-093385

93  Medicinal product by Effects on drug levels Recommendation therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning (dose in mg) co-administration with 245 mg tenofovir disoproxil Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma (400 mg/100 mg q.d.) + AUC: ↔ concentrations of tenofovir Atazanavir/Ritonavir Cmax: ↔ resulting from (300 mg q.d./100 mg q.d.) + co-administration of tenofovir Emtricitabine/Tenofovir GS-3310072: disoproxil, disoproxil AUC: ↔ sofosbuvir/velpatasvir and (200 mg/245 mg q.d.) Cmax: ↔ atazanavir/ritonavir may Cmin: ↑ 42% increase adverse reactions related to tenofovir disoproxil, Velpatasvir: including renal disorders. The AUC: ↑ 142% safety of tenofovir disoproxil Cmax: ↑ 55% when used with Cmin: ↑ 301% sofosbuvir/velpatasvir and a pharmacokinetic enhancer Atazanavir: (e.g. ritonavir or cobicistat) AUC: ↔ has not been established. Cmax: ↔ Cmin: ↑ 39% The combination should be used with caution with Ritonavir: frequent renal monitoring (see AUC: ↔ section 4.4). Cmax: ↔ Cmin: ↑ 29%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)